Clinical safety profile of cefodizime.
Data from ten clinical trials involving 1189 patients treated with 1 g bd of cefodizime iv or im were analysed for adverse effects and abnormal laboratory test results. In total, side-effects possibly or probably related to cefodizime occurred in only 1.34% of patients. In a separate analysis of 138 geriatric patients, the incidence was less than 1%. The most frequent clinical adverse effects were related to the gastrointestinal tract or were skin reactions. In laboratory evaluation, the haematological parameters showed the expected changes in response to the cure of the infectious process. The hepatic function tests showed increased values in 0.7%-3% of cases (depending on the test). Serum creatinine was increased in less than 1% of the cases.
Perianu
M R
MR
Medical Department Roussel-Uclaf, Romainville, France
D000328:Adult; D000368:Aged; D002439:Cefotaxime / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007677:Kidney Function Tests; D008111:Liver Function Tests; D008875:Middle Aged; D012871:Skin Diseases / Q000139:chemically induced
D003404:Creatinine; D002439:Cefotaxime; C033356:cefodizime